MX2015002378A - Composicion ansiolitica, formulacion y metodo de uso. - Google Patents

Composicion ansiolitica, formulacion y metodo de uso.

Info

Publication number
MX2015002378A
MX2015002378A MX2015002378A MX2015002378A MX2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
nmda receptor
composition
subject
ansiolitic
Prior art date
Application number
MX2015002378A
Other languages
English (en)
Spanish (es)
Inventor
Stuart L Weg
Original Assignee
Stuart L Weg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart L Weg filed Critical Stuart L Weg
Publication of MX2015002378A publication Critical patent/MX2015002378A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015002378A 2012-08-23 2013-08-23 Composicion ansiolitica, formulacion y metodo de uso. MX2015002378A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
MX2015002378A true MX2015002378A (es) 2015-09-25

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002378A MX2015002378A (es) 2012-08-23 2013-08-23 Composicion ansiolitica, formulacion y metodo de uso.

Country Status (11)

Country Link
US (4) US20140057988A1 (cg-RX-API-DMAC7.html)
EP (2) EP2887930A4 (cg-RX-API-DMAC7.html)
JP (2) JP6722453B2 (cg-RX-API-DMAC7.html)
KR (1) KR20150096370A (cg-RX-API-DMAC7.html)
CN (1) CN104902883A (cg-RX-API-DMAC7.html)
AU (1) AU2013305580A1 (cg-RX-API-DMAC7.html)
BR (1) BR112015003796A2 (cg-RX-API-DMAC7.html)
IL (1) IL237340A0 (cg-RX-API-DMAC7.html)
MX (1) MX2015002378A (cg-RX-API-DMAC7.html)
SG (1) SG11201501292UA (cg-RX-API-DMAC7.html)
WO (1) WO2014031975A1 (cg-RX-API-DMAC7.html)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111643449A (zh) 2013-03-15 2020-09-11 詹森药业有限公司 S-盐酸氯胺酮的药物组合物
HUE045982T2 (hu) * 2013-03-15 2020-01-28 Janssen Pharmaceutica Nv S-Ketamin-hidroklorid gyógyászati kompozíció
JP6462663B2 (ja) 2013-04-12 2019-01-30 アイカーン スクール オブ メディシン アット マウント シナイ 心的外傷後ストレス障害を処置するための方法
HRP20211629T1 (hr) 2013-09-13 2022-02-04 National University Corporation Chiba University Primjena r-ketamina i njegove soli kao lijekova
US10098854B2 (en) 2014-08-13 2018-10-16 Janssen Pharmaceutica Nv Method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
MA40620A (fr) 2014-09-15 2016-03-24 Janssen Pharmaceutica Nv Régimes posologiques spécifiques au génotype val66met (snp rs6265) et méthodes pour le traitement de la dépression
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
EA201792571A1 (ru) * 2015-05-22 2018-06-29 Вистаджен Терапьютикс, Инк. Терапевтическое применение l-4-хлорокинуренина
JP6845162B2 (ja) 2015-06-27 2021-03-17 シェノックス・ファーマシューティカルズ・エルエルシー ケタミン経皮送達システム
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
US11173153B2 (en) * 2015-09-08 2021-11-16 The Children's Hospital Of Philadelphia Methods of diagnosing and treating anxiety disorder
WO2017087691A1 (en) * 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
WO2019094596A1 (en) 2017-11-09 2019-05-16 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3075038B1 (fr) * 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
KR20240011237A (ko) 2017-12-22 2024-01-25 얀센 파마슈티카 엔브이 우울증 치료를 위한 에스케타민
ES2907692T3 (es) 2017-12-29 2022-04-26 Celon Pharma Sa Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento
CN111936127A (zh) 2018-02-15 2020-11-13 国立大学法人千叶大学 炎症性疾病或骨病的预防或治疗剂及医药组合物
CN112533595A (zh) 2018-05-04 2021-03-19 感知神经科学公司 治疗物质滥用的方法
WO2020041329A1 (en) * 2018-08-20 2020-02-27 Yale University Combination therapy for treating or preventing depression or other mood diseases
US12115601B2 (en) 2019-02-22 2024-10-15 Harima Chemicals, Incorporated Method of applying solid brazing material, method of producing coated workpiece, application apparatus, and roll-shaped solid brazing material
EP3934632A4 (en) 2019-03-05 2022-11-23 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
EP3968977A4 (en) * 2019-05-15 2023-01-11 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS AGAINST AFFECTIVE DISORDERS INDUCED BY STRESS AND THEIR ASSOCIATED SYMPTOMS
WO2020240279A1 (en) * 2019-05-31 2020-12-03 Lionheart Pharmaceuticals Aps Intranasal administration of ketamine to cluster headache patients
IL294485A (en) 2020-01-22 2022-09-01 Seelos Therapeutics Inc Reduction of side effects of nmda antagonists

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
CN101466364A (zh) * 2006-03-22 2009-06-24 纽约大学西奈山医学院 鼻内施用氯胺酮治疗抑郁症
EP2139848A1 (en) * 2007-04-26 2010-01-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
BR112015003796A2 (pt) 2017-07-04
WO2014031975A1 (en) 2014-02-27
EP2887930A4 (en) 2016-03-23
US20250255834A1 (en) 2025-08-14
US20220160655A1 (en) 2022-05-26
SG11201501292UA (en) 2015-05-28
CN104902883A (zh) 2015-09-09
US20180235906A1 (en) 2018-08-23
JP6722453B2 (ja) 2020-07-15
EP3878442A1 (en) 2021-09-15
JP2018162302A (ja) 2018-10-18
US20140057988A1 (en) 2014-02-27
KR20150096370A (ko) 2015-08-24
IL237340A0 (en) 2015-04-30
AU2013305580A1 (en) 2015-04-09
JP6771512B2 (ja) 2020-10-21
EP2887930A1 (en) 2015-07-01
JP2016501828A (ja) 2016-01-21

Similar Documents

Publication Publication Date Title
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
ECSP17022931A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alchólico
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
UY35210A (es) Inhibidores de autotaxina
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
GT201400196A (es) Compuestos de heterociclilo
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
SV2017005530A (es) Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.
UY32734A (es) Compuestos agonistas del receptor esfingosina 1-fosfato
CO2017008031A2 (es) Compuestos con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico